

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 15, 2026

---

**BONE BIOLOGICS CORPORATION**

(Exact name of registrant as specified in its charter)

---

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-40899**  
(Commission  
File Number)

**42-1743430**  
(IRS Employer  
Identification No.)

**2 Burlington Woods Drive, Ste. 100**  
**Burlington, MA**  
(Address of principal executive offices)

**01803**  
(Zip Code)

Registrant's telephone number, including area code: **(781) 552-4452**

(Former name or former address, if changed since last report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

| Title of each class                                            | Trading Symbol(s) | Name of each exchange on which registered |
|----------------------------------------------------------------|-------------------|-------------------------------------------|
| Common Stock, par value \$0.001 per share                      | BBLG              | Nasdaq Capital Market                     |
| Warrants to Purchase Common Stock, par value \$0.001 per share | BBLGW             | Nasdaq Capital Market                     |

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

---

---

**Item 8.01 Other Events.**

On July 15, 2026, the Board of Directors (the “Board”) of Bone Biologics Corporation (the “Company”) determined to postpone the 2026 annual meeting of stockholders (the “Annual Meeting”), which was previously scheduled to be held on August 11, 2026. The Company intends to file a Definitive Proxy Statement on Schedule 14A with the Securities and Exchange Commission that includes an additional proposal to be voted on by stockholders and the Board determined additional time was necessary for stockholders to consider the proxy materials. The Annual Meeting will be held at the Company’s offices, 2 Burlington Woods Drive, Ste 100, Burlington, MA 01803, on September 28, 2026 at 11:30 a.m. Eastern Time and the new record date for the Annual Meeting will be August 6, 2026. In connection with the postponement, the deadline for stockholder submissions of director nominees or proposals to bring other business before the Annual Meeting is now ten calendar days following the date of this Current Report on Form 8-K, or July 26, 2026.

---

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

### BONE BIOLOGICS CORPORATION

Date: July 16, 2026

By: /s/ Jeffrey Frelick

Jeffrey Frelick

Chief Executive Officer

---